menu search

RPHM / Reneo Pharmaceuticals: Buy Before Upcoming Pivotal Data Drop

Reneo Pharmaceuticals: Buy Before Upcoming Pivotal Data Drop
Reneo Pharmaceuticals is developing mitochondrial disease therapies, with its lead program being mavodelpar or REN001. Mavodelpar has shown promising results in increasing fatty acid oxidation and improving muscle strength in clinical trials. The company expects topline results from a pivotal trial in primary mitochondrial myopathy in 4Q23, with potential approval and launch in late 2024. Read More
Posted: Oct 29 2023, 20:00
Author Name: Seeking Alpha
Views: 042531

RPHM News  

Reneo Pharmaceuticals: Buy Before Upcoming Pivotal Data Drop

By Seeking Alpha
October 29, 2023

Reneo Pharmaceuticals: Buy Before Upcoming Pivotal Data Drop

Reneo Pharmaceuticals is developing mitochondrial disease therapies, with its lead program being mavodelpar or REN001. Mavodelpar has shown promising more_horizontal

Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences

By GlobeNewsWire
September 6, 2022

Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences

IRVINE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the more_horizontal


Search within

Pages Search Results: